ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s ...

A recent study confirms that the 100-year-old BCG vaccine does not protect against COVID-19, challenging early assumptions ...

Artificial intelligence (AI) is reshaping the way businesses operate in the retail and e-commerce spaces. From streamlining ...

BCG highlights how governments are reshaping energy policies to balance sustainability, security and affordability, focusing ...

Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...

BLADDER cancer is classified as either non-muscle invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) ...

Nadofaragene firadenovec intravesical gene therapy continues to show promise in treating BCG-unresponsive NMIBC bladder cancer.

Business leaders are ambitious about agentic AI but have legitimate concerns about data privacy, security, and compliance.

ImmunityBio (IBRX) announced U.S. Urology Partners, one of the nation’s largest independent providers of urology and related specialty ...

The Federal Maritime Commission wants to know whether foreign countries and their shipping companies are causing supply chain ...

ImmunityBio faces significant operational risks due to reliance on international BCG supplies and competition from Adstiladrin in NMIBC treatment. Financially, ImmunityBio struggles with high cash ...

Moreover, Indian ITes cannot succeed in implementing use cases of Agentic AI without a strong foundation in Gen AI.